Overview

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Riociguat
Criteria
Inclusion Criteria:

- Male and female patients with symptomatic pulmonary hypertension due to left
ventricular systolic dysfunction despite optimized heart failure therapy

Exclusion Criteria:

- Types of pulmonary hypertension other than group 2.1 of Dana Point Classification